Search
Connecting patients everywhere to precision oncology
In precision oncology, timely access to biomarker results is critical for informing treatment decisions. However, long turnaround times and limited tissue availability may limit or delay access to biomarker information for molecular profiling.
The Ion Torrent Oncomine Dx Express Test (CE-IVD) is designed to address these challenges by enabling laboratories to deliver relevant genomic profiles in as little as 24 hours, facilitating faster, more informed treatment decisions.
With an automated workflow on the Ion Torrent Genexus Dx System, low nucleic acid input requirements, and support for multiple variant classes across tissue and liquid biopsy samples, the assay enables genomic profiling in local laboratories without the need for extensive next-generation sequencing (NGS) expertise.
What can Oncomine Dx Express Test enable you to do?
Deliver NGS results in as little as 24 hours from tissue sample to report
Enable genomic profiling from tissue and liquid biopsy samples with results available next day, supporting timely, more informed treatment decisions.
Bring precision oncology closer
to your patients
Support in-house testing with an automated NGS workflow, bringing genomic profiling to local laboratories.
Get results for more patients, even with
limited sample
Utilize low DNA, RNA, and cfTNA input to support testing from small or challenging tissue samples, with option for liquid biopsy analysis.
Hear from experts using the Oncomine Dx Express Test
Bence Sipos, MD
Molecular Pathology
Baden-Württemberg, Stuttgart, Germany
Abstract:
Prof. Bence Sipos shared practical, pathology-centered insights into adopting rapid NGS for oncology testing. He discussed the growing clinical need for comprehensive molecular characterization from minimal FFPE samples and highlighted the Oncomine Dx Express Test as a solution balancing speed, sensitivity, and sample efficiency. His laboratory in Stuttgart performed ~5,000 NGS tests annually, achieving ≤3-day turnaround time in over 80% of cases and <1% drop-off rate.
Case studies in NSCLC and other solid tumors highlighted the utility of the Oncomine Dx Express Test in genomic profiling and delivery of timely genomic information for oncology testing. Dr. Sipos concluded that rapid, reliable NGS is now equivalent in turnaround and dependability to traditional pathology methods like IHC—representing a “quiet revolution” in molecular diagnostics.
Steve Stone
Managing Director
Argent Global Services
Abstract:
See how automation and workflow design impact speed, efficiency, and cost in real‑world NGS testing.
As oncology testing demand grows, labs are under pressure to deliver accurate results faster with fewer hands and tighter budgets. In this webinar, you’ll see real time‑and‑motion data comparing two NGS workflows (amplicon- based Oncomine Dx Express Test and hybrid capture based NGS workflow) for routine precision oncology, and learn how automation can reduce touchpoints, shorten turnaround time, and support sustainable scaling. You’ll walk away with clarity on:
- Hands-on time vs turnaround time: what actually changes when workflows are redesigned
- How automation supports efficiency in precision oncology testing
- Where labs can cut bottlenecks without compromising quality
- Ways to optimize resources as testing volumes grow
NGS made easy—2 instruments, 1 software, and as little as 20 minutes of hands-on time
The Genexus Dx System automates the NGS workflow from patient samples to reports with only two user touchpoints and as little as 20 minutes of hands-on time.
Pre-treated FFPE tissue sections are loaded onto the Genexus Dx Purification System and the instrument performs automated purification and quantification of DNA and RNA.
Library preparation, template preparation, sequencing, analysis, and reporting are performed by the Genexus Dx Integrated Sequencer. Throughout this procedure, sample and reagent information is recorded and tracked by one integrated software. This highly automated workflow helps reduce laboratory staff burden and the potential for human errors and alleviates the need for specialized bioinformatics expertise.
Oncomine Dx Express Test workflow
Ordering information
For In Vitro Diagnostic Use.
Not available in all countries.
PMR-004755
Oncomine Dx Express Test (CE-IVD) Abbreviated Intended Use: The Oncomine Dx Express Test is a qualitative in vitro diagnostic test that uses targeted next-generation sequencing (NGS) technology, the Ion Torrent Genexus Dx System to detect deletions, insertions, substitutions and copy number gain present in 42 genes and fusions in 18 genes from DNA and RNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples. Oncomine Dx Express Test also detects deletions, insertions, substitutions in 42 genes and fusions in 7 genes from cfTNA extracted from plasma samples. The Oncomine Dx Express Test is intended to provide clinically relevant tumor mutation profiling information to be used by qualified health care professionals in accordance with professional guidelines as an aid in therapy management of cancer patients with solid malignant neoplasms using FFPE samples and as an aid in therapy management of cancer patients with non-small cell lung cancer using plasma samples. It is not conclusive or prescriptive for labeled use of any specific therapeutic product.